Patient characteristics, treatment patterns and outcomes of patients enrolled in the Tezepelumab Patient Access Programme; a retrospective, observational medical chart review conducted in UK severe asthma centres - TPAP

Study identifier:D5180R00027

ClinicalTrials.gov identifier:NCT06455462

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Patient characteristics, treatment patterns and outcomes of patients enrolled in the Tezepelumab Patient Access Programme; a retrospective, observational medical chart review conducted in UK severe asthma centres

Medical condition

Severe Asthma

Phase

N/A

Healthy volunteers

No

Study drug

Tezepelumab

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

18 Years - 100 Years

Date

Study Start Date: 22 Apr 2024
Estimated Primary Completion Date: 23 Sept 2024
Estimated Study Completion Date: 23 Sept 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria